TRACER
Brief description of study
There is evidence that GALAD, a score that incorporates 3 blood based biomarkers and patient age and sex may be more effective than standard of care screening at detecting HCC early in patients with liver cirrhosis or chronic hepatitis B. Patients undergoing liver cancer screening will be enrolled, then randomized into either a cohort screened with GALAD or a cohort screened with standard of care. Patients will also answer questionnaires annually.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
